OpenNeedle Ask your own

Question explored with the scientific record

Conversation so far

  1. 1 Why is absolute risk more useful than relative risk?
  2. 2 How do I calculate absolute risk and NNT for my own situation?

Answered on this page ↓

How do I calculate absolute risk and NNT for my own situation?

Sep 7, 2026 · 6 sources used · OpenNeedle synthesis
The short version: you can calculate your own absolute risk and NNT, but the hard part is finding an honest baseline risk for your specific situation, not the arithmetic.

The math is simple. Absolute risk is your chance of the outcome without treatment, minus your chance with treatment. NNT is 100 divided by that difference, when both are expressed as percentages. If your baseline risk is 20 in 100 and treatment drops it to 10 in 100, the absolute reduction is 10 in 100 and the NNT is 10. If your baseline risk is 2 in 100 and treatment drops it to 1 in 100, the reduction is 1 in 100 and the NNT is 100 [3].

The trap is the baseline. Most published NNTs come from trials on specific populations, and the same relative reduction maps to wildly different NNTs depending on who is treated [3]. A drug that looks impressive in a high-risk trial can be nearly worthless in a low-risk patient. So you need three honest inputs: your baseline risk over the relevant time window, the relative risk reduction from the intervention, and the harm rate. The first is usually the weakest link. Your doctor may quote a risk calculator, but those models are only as good as their calibration, and a miscalibrated model can produce net harm when used to decide treatment [13].

The evidence retrieved here is thin for your exact question. It gives worked NNT examples for pain drugs, bipolar depression, and Alzheimer's [4, 5, 6, 8], but no tool for personalizing your own baseline. What matters is that you demand the absolute numbers, not just the relative reduction, and that you ask who funded the trial that produced the NNT. Industry-funded studies are marketing with a Methods section.

My call: do the arithmetic yourself, but treat any baseline risk you are given as an estimate with real uncertainty, and ask for the absolute numbers behind every NNT. Confidence: high on the method, low on the availability of honest personalized baselines.

Keep digging

Sources used 6

  1. FORGEPHAST: A fast, haplotype-first complex population and phenotype simulator for biobank-scale simulation primary study Strong

    FORGEPHAST is a Python framework for reference-panel-based synthetic haplotype and phenotype generation that preserves donor-panel population-genetic properties, scales to 250,000 diploids, and shows PRS method ranking depends on phenotype architecture and ancestry.

    DOI: 10.64898/2026.07.30.741657
  2. Antiepileptic Drugs in Treatment of Pain Caused by Diabetic Neuropathy Journal of Pain and Symptom Management (2007) Thin

    This meta-analysis evaluates the effectiveness of various antiepileptic drugs in managing pain associated with diabetic neuropathy, concluding that pregabalin is the most effective with the lowest number needed to treat for significant pain relief.

    DOI: 10.1016/j.jpainsymman.2006.10.023
  3. Balancing benefits and harms of treatments for acute bipolar depression Journal of Affective Disorders (2014) Thin

    This study evaluates the efficacy and safety of various treatments for acute bipolar depression, comparing the number needed to treat (NNT) for response and the number needed to harm (NNH) for side effects among FDA-approved and unapproved medications.

    DOI: 10.1016/S0165-0327(14)70006-0
  4. Single dose oral diclofenac for acute postoperative pain in adults Cochrane Database of Systematic Reviews (2004) Thin

    This study evaluates the efficacy of single-dose oral diclofenac for treating acute postoperative pain in adults, finding it effective with no significant difference in adverse effects compared to placebo.

    DOI: 10.1002/14651858.CD004768
  5. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis International Journal of Geriatric Psychiatry (2004) Thin

    This study evaluates the clinical efficacy of memantine in treating moderately severe to severe Alzheimer's disease using a 'number needed to treat' (NNT) analysis, finding that memantine has a valuable place in clinical management with low NNTs and minimal harm compared to plac…

    DOI: 10.1002/gps.1166
  6. Understanding the Value of Individualized Information: The Impact of Poor Calibration or Discrimination in Outcome Prediction Models Medical Decision Making (2017) Thin

    A simulation-based evaluation of the value and risks of individualized, risk-based medical decisions (EVIC) showing that well-calibrated, discriminative prediction models can add substantial value to treatment decisions, while poor calibration can produce net harm.

    DOI: 10.1177/0272989X17704855

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question